Venker Eric

Venker Eric, President & CEO of Immunovant, has demonstrated a consistent pattern of selling shares in Roivant Sciences (ROIV) over recent months, with no recorded purchases. According to SEC Form 4 filings, Eric has executed 53 transactions exclusively involving ROIV, with total sales exceeding $85.2 million against total buys of $33.7 million—a net selling bias. The most recent activity includes 12 sales between October 2025 and March 2026, with notable transactions such as a $5.6 million sale on March 17, 2026, and a $5.3 million sale on February 13, 2026. Many of these sales were accompanied by smaller "M"-coded transactions, likely representing tax withholdings or option exercises, such as the $770,000 transaction on March 17, 2026. The selling trend has been persistent, with multiple seven-figure disposals in late 2025, including a $7.0 million sale on October 15, 2025, and a $5.4 million sale the following day. Smaller periodic sales, such as a $336,813 transaction on October 13, 2025, suggest a structured divestment strategy rather than a single liquidation event. The absence of any recent buys indicates Eric has been reducing his position in ROIV systematically over the observed period. While the filings do not disclose motives, the data reflects a clear directional shift toward decreasing his stake in the company.